ASCRS 2024: A retrospective study shows iStent's impact on medication burden in surgical and non-surgical patient groups

News
Video

At ASCRS, Dr Rom Kandavel discusses iStent outcomes for patients who have undergone laser peripheral iridotomy, trabeculectomy and SLT

At this year's ASCRS meeting, we caught up with Rom Kandavel, MD, of Colvard-Kandavel Eye Center in Los Angeles, California. He discussed the paper he presented at the meeting, which focused on IOP lowering and medication burden for patients who received the iStent inject.

Editor's note: The below transcript has been lightly edited for clarity.

Rom Kandavel, MD: Thank you so much for allowing me to speak today, I was able to present a paper at this year's ASCRS meeting in regards to the 12-month data following patients who received the iStent inject who had surgery previously or no surgery previously. And what we did is we did a retrospective study, and we collected about 100 patients. There were 34 patients who receive previous surgery. The surgery that we defined was laser peripheral iridotomy, selective laser trabeculoplasty (SLT) and trabeculectomy. And when we looked at those patients, and we looked at the medication burden, as well as the intraocular pressure, we were able to see a significant trend for improvement after iStent inject placement at the 12-month mark.

In fact, the surgical group started out with lower intraocular pressures but more medication burden. And the non surgical group, as being less severe glaucoma, were maintained at a higher pressure. So they had a higher starting pressure. In the end, they had less medications. Therefore, we saw a significant reduction in IOP in both groups. The prior surgical group started at 15.85 and ended at 13.2 average, at the 12 month mark. The non surgical group had started at 17.12 and then ended at 13.84. But when we looked at medication burden, the prior surgical group had started on average about 1.82 medications, but ended at 1.34. However, the non prior surgical group started out with 1.32 and ended at 1.3. And that was not statistically significant.

But what we did see was that when patients received a iStent inject despite having a baseline pressure that was different ended up with the same mean pressure at the 12 month mark. Similarly, patients who had the iStent inject in the surgical group versus the non surgical group enjoyed around a 35% independence from drops at the 12 month mark. So a similar amount of medication free treatment after the iStent inject in two dissimilar groups, one surgical, one non surgical. So there's really good evidence, I think, in this study, to at least, you know, talk about using iStent inject in previous patients with laser peripheral iridotomy as well as SLT and trabeculectomy.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.